Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 14;12:705539. doi: 10.3389/fimmu.2021.705539

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Rodríguez-Martín, Rojas, Macchi, Franceschi, Russo, Sevilla, Donofrío and Martín

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effect of BoHV-4-A-PPRV-H-ΔTK vaccination in ovine PBMC populations. PBMCs obtained from the three treatment groups [PBS (black), BoHV-4-A-ΔTK (blue), and BoHV-4-A-PPRV-H-ΔTK (red)] were stained with different monoclonal antibodies and analyzed by flow cytometry at different time points [pre-immunization (D0), pre-challenge (D42), and days 2, 4, 7, 9, 11, and 14 post-challenge (PC)]. Average percentage of (A) CD4⁺ cell population, (B) CD8⁺ cell population, (C) WC1⁺ (γδ T cell) population, (D) B-cell⁺ population, (E) CD14⁺ cell population, (F) CD14⁺ CD16⁺ cell population, and (G) CD16⁺ CD14⁻ cell population for each sheep group were plotted. *p < 0.05 one-way ANOVA test (BoHV-4-A-PPRV-H-ΔTK vs. BoHV-4-A-ΔTK and PBS control groups). The black arrow (D42) denotes the time of virulent PPRV ICV’89 challenge in all animals.